Search Results - DeLuca-Carter, Louise

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    51887 Lebrikizumab Demonstrates Sustained Efficacy in Adolescent Patients Through 2 Years of Continuous Treatment: Results From ADjoin Long-Term Extension

    51887 Lebrikizumab Demonstrates Sustained Efficacy in Adolescent Patients Through 2 Years of Continuous Treatment: Results From ADjoin Long-Term Extension by Paller, Amy, Torrelo, Antonio, Yang, Chin-Yi, Heath, Candrice, Flohr, Carsten, Weidinger, Stephan, Elmaraghy, Hany, DeLuca-Carter, Louise, Yang, Fan Emily, Armengol, Clara, Eichenfield, Lawrence

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Lebrikizumab Maintains Improvements in the Patient-Oriented Eczema Measure Through 2 Years of Treatment in Patients With Moderate-to-Severe Atopic Dermatitis

    Lebrikizumab Maintains Improvements in the Patient-Oriented Eczema Measure Through 2 Years of Treatment in Patients With Moderate-to-Severe Atopic Dermatitis by Rosmarin, David, Wollenberg, Andreas, Boguniewicz, Mark, Jack, Carolyn, Barbarot, Sebastien, Shi, Vivian, de Bruin-Weller, Marjolein, DeLuca-Carter, Louise, Pierce, Evangeline, Hu, Chaoran, Liu, Chunyuan, Crane, Heidi, Bardolet, Laia, Steinhoff, Martin

    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    494 - Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis

    494 - Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis by Guttman-Yassky, Emma, Weidinger, Stephan, Simpson, Eric, Gooderham, Melinda, Irvine, Alan, Spelman, Lynda, Silverberg, Jonathan, Elmaraghy, Hany, DeLuca-Carter, Louise, Piruzeli, Maria Lucia Buziqui, Hu, Chaoran, Yang, Fan Emily, Pierce, Evangeline, Bardolet, Laia, Thaci, Diamant

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Atopic Dermatitis Treatment with Topical Therapy Alone Results in Persistent Elevated Disease Severity and High Disease Control Dissatisfaction: Real-World Health Care Professional and Patient Perspectives

    Atopic Dermatitis Treatment with Topical Therapy Alone Results in Persistent Elevated Disease Severity and High Disease Control Dissatisfaction: Real-World Health Care Professional... by Lio, Peter, Golant, Alexandra, Chovatiya, Raj, Geng, Bob, DeLuca-Carter, Louise Ann, Dawson, Zach, Pierce, Evangeline, Haughton, James, Anderson, Peter, Piercy, James, Stein-Gold, Linda

    Published in Skin (Milwood, N.Y.)
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis

    Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis by Guttman-Yassky, Emma, Weidinger, Stephan, Simpson, Eric, Gooderham, Melinda, Irvine, Alan, Spelman, Lynda, Silverberg, Jonathan, Elmaraghy, Hany, DeLuca-Carter, Louise, Buziqui Piruzeli, Maria Lucia, Hu, Chaoran, Yang, Fan Emily, Pierce, Evangeline, Bardolet, Laia, Thaci, Diamant

    Published in Skin (Milwood, N.Y.)
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: